One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to DSIP / Emideltide in België. FDA-flagged unapproved research-market peptide identity.

Current source route

DSIP / Emideltide in België

Direct answer / België

Can you buy DSIP / Emideltide in België?

FDA-flagged unapproved research-market peptide identity

DSIP, also called emideltide or delta sleep-inducing peptide, is tracked here as a US research-market identity. FDA has identified emideltide among bulk substances that may present significant safety risks in compounding and notes important gaps in human safety information. That does not establish an approved medicine, a lawful local supply route, seller identity, product quality, or suitability for use in any destination.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check BelgiëResearch price board
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordFDA-flagged unapproved research-market peptide identity

What DSIP / Emideltide resolves to

DSIP, also called emideltide or delta sleep-inducing peptide, is tracked here as a US research-market identity. FDA has identified emideltide among bulk substances that may present significant safety risks in compounding and notes important gaps in human safety information. That does not establish an approved medicine, a lawful local supply route, seller identity, product quality, or suitability for use in any destination.

Evidence lane
Research price board
Current record
2 of 3 rows in stock
Checked
Jul 23, 2026
Delta sleep-inducing peptideEmideltideDSIP nonapeptidedelta sleep-inducing peptidedelta sleep inducing peptide
Destination recordFAGG-product- en apotheekcontrole vereist

What België still has to prove

Een Nederlandstalige gids voor zoekopdrachten naar peptiden, peptidegeneesmiddelen, middelen voor gewichtsbeheersing en onderzoeksmaterialen in België. Zoek eerst het exacte geneesmiddel in de databank van het FAGG en controleer daarna de openbare apotheek en haar website via de officiële internetapotheekroute, zonder taal, europrijs of Belgische bezorging als bewijs te behandelen.

Comparison mode
EUR / FAGG-geneesmiddelen- en internetapotheekrecords
Price coverage
Geen gekwalificeerde Belgische verkoperstabel
Guide updated
18 juli 2026
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail